Search
for
Sort by
Research 751–780 of 1000+
- Journal Watch
- Low-level light therapy and hair loss
- Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk
- Plain language summaries
- Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies
- Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee
- NEW PROPRIETARY BRANDS: Gabapentin
- NEW PROPRIETARY BRANDS: Cephalexin
- New drugs: Agalsidase beta
- NEW FORMULATIONS: Sodium cromoglycate
- NEW FORMULATIONS: Glatiramer acetate
- Spironolactone
- Efficacy and Safety of Platelet-Rich Plasma in Melasma: A Systematic Review
- Androgens and Female Sexual Function and Dysfunction—Findings From the Fourth International Consultation of Sexual Medicine
- Avicequinone C Isolated from Avicennia marina Exhibits 5α-Reductase-Type 1 Inhibitory Activity Using an Androgenic Alopecia Relevant Cell-Based Assay System
- Screening for 21-hydroxylase–deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study
- Alopecia: evaluation and treatment
- A Novel Effect of Acyclovir on Hair Growth in BALB/c Mice: A Promising Future for Finding a New Topical Drug for the Treatment of Hirsutism
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Polycystic ovary syndrome
- Pharmacologic Treatment of Polycystic Ovary Syndrome
- Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women
- Polycystic ovary syndrome
- Nonclassic congenital adrenal hyperplasia and the heterozygote carrier
- Cyproterone Acetate: A Genotoxic Carcinogen?
- Exploring the therapeutic potential of phytochemicals apigenin and ellagic acid in managing polycystic ovarian syndrome and its comorbidities: a comprehensive review
- SUMMARIES OF PAPERS
- BOOK REVIEWS
- Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey
- Psoriasis